Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 10/20 | 0.67 |
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | NAAA | Q02083 | 3/20 | 0.55 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.55 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4811184 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL8355975 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL7305201 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL292692 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL3842001 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL7472317 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL10702251 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL8930393 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL294158 | 0.98 | — | — | |
| SCHEMBL42512 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | EMORY UNIVERSITY | 2002-09-12 | — | — | US | disclosed |
| WO-2002047679-A2 | NONPEPTIDE AGONISTS AND ANTAGONISTS OF VASOPRESSIN RECEPTORS | EMORY UNIVERSITY (US) | 2002-06-20 | — | — | WO | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | disclosed |
| EP-0581166-A1 | Benzimidazoles, process for their preparation and their use as angiotensin-II antagonists | Dr. Karl Thomae GmbH (DE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
| EP-0470543-A1 | Heterocyclic imidazoles, remedies containing them and processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | AVPR1A, AVPR2, AVPR1B | EPHX1 2133/4885CASP2 3647/4885NAAA 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.